Speciality
Spotlight

 




           

Clinical Pharmacology

       

     





Meloxicam Adverse Reactions

    

  • Richard M
    Martin, Pipasha Biswas and Ronald D. Mann (Drug
    Safety Research Unit, Bursledon Hall, Southampton
    and School of Medicine, Faculty of Medicine and
    Biological Sciences, University of Southampton, UK).




    The incidence of adverse events and risk factors
    for upper gastrointestinal disorders associated with
    meloxicam use amongst 19087 patients in general
    practice in England: cohort study.





    Br.J.Clin.Pharmacol, 50(1),July 2000, 35-42.


      


    Meloxicam,
    a novel NSAID, may produce fewer gastrointestinal 
    adverse effects than other NSAIDs – as it
    preferentially inhibits inducible enzyme
    cyclo-oxygenase-2 relative to the constitutive
    isoform cyclo-oxygenase-1.




      

    Aim of the
    study, was to determine rate of adverse events
    associated with meloxicam use in general practice,
    stratify these rates by selected risk factors, and
    to identify signals of previously unsuspected
    adverse events associated with meloxicam.




      

    All
    patients prescribed meloxicam in England between
    December ’96 and March ’97 were identified. There
    were 19087 patients in the study.




      

    Short
    questionnaires were sent to all prescribers asking
    about adverse events experienced within 6 months of
    the first prescription.




      

    Conclusion
    was that in the absence of gastro-intestinal risk
    factors, incidence of GI disturbance was low. Such risk factors should be carefully
    reviewed prior to prescribing meloxicam.

     




  
 



 

     

Speciality Spotlight

 

           
Clinical Pharmacology
       

     

Meloxicam Adverse Reactions
    

  • Richard M Martin, Pipasha Biswas and Ronald D. Mann (Drug Safety Research Unit, Bursledon Hall, Southampton and School of Medicine, Faculty of Medicine and Biological Sciences, University of Southampton, UK).


    The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19087 patients in general practice in England: cohort study.


    Br.J.Clin.Pharmacol, 50(1),July 2000, 35-42.
      
    Meloxicam, a novel NSAID, may produce fewer gastrointestinal  adverse effects than other NSAIDs – as it preferentially inhibits inducible enzyme cyclo-oxygenase-2 relative to the constitutive isoform cyclo-oxygenase-1.


      
    Aim of the study, was to determine rate of adverse events associated with meloxicam use in general practice, stratify these rates by selected risk factors, and to identify signals of previously unsuspected adverse events associated with meloxicam.


      
    All patients prescribed meloxicam in England between December ’96 and March ’97 were identified. There were 19087 patients in the study.


      
    Short questionnaires were sent to all prescribers asking about adverse events experienced within 6 months of the first prescription.


      
    Conclusion was that in the absence of gastro-intestinal risk factors, incidence of GI disturbance was low. Such risk factors should be carefully reviewed prior to prescribing meloxicam.
     

    

 

By |2022-07-20T16:42:13+00:00July 20, 2022|Uncategorized|Comments Off on Meloxicam Adverse Reactions

About the Author: